Background: Pharmaceutical expenditure grow strongly in most health care systems. Especially high prices of new drugs are perceived to be driver of growth which might threaten the sustainability of financing drugs. Objective: The study aims to analyse a) whether German health policies can...

Seit 30 Jahren erlebt der Apotheker und promovierte Pharmazeut Franz Stadler alle Tricks und Betrügereien der Arzneimittelindustrie. Als Experte und Insider packt er jetzt aus und seziert messerscharf diese Geschäfte, ihre Player und die Geldflüsse dahinter. Heraus kommt ein komplexes System,...

A non-trivial fraction of people cannot afford to buy pharmaceutical products at unregulated market prices. This paper analyses the public insurance of a patent-protected pharmaceutical product in terms of price controls and socially optimal third-degree price discrimination. First, the paper...

A non-trivial fraction of people cannot afford to buy pharmaceutical products at unregulated market prices. Therefore, the paper analyzes the public insurance of the pharmaceutical products in terms of price controls and the socially optimal third-degree price discrimination. It characterizes...